Healthy Q1 prompts guidance upgrade
13/05/22 -"Genmab reported a healthy set of Q1 results. This impressive performance was witnessed across the offerings, which were again led by Darzalex. Despite maintaining aggressive spending plans, the 2022 ..."
Pages
51
Language
English
Published on
13/05/22
You may also be interested by these reports :
25/05/22
Considering the group was already facing multiple headwinds – deteriorating generics pricing environment in the US, market share losses for its ...
18/05/22
We have updated our model to incorporate the impact of the spin-off of the API (active pharmaceutical ingredient) business, which had listed ...
18/05/22
Given the sustained recovery in the plasma supply – now back to pre-pandemic levels – Grifols has been benefiting from a recovery in investor ...
17/05/22
As Sensei has prioritised development of SNS-101 over the SNS-401-NG programme – possibly to manage cash burn, considering the recent decline in ...